20 May 2013
Keywords: merck, serono, matuzumab, misses, ph, ii, mcrc
Article | 03 September 2007
German Swiss drugmaker Merck Serono, a division of Merck KGaA, says that a Phase II trial investigating the humanized monoclonal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 September 2007
17 May 2013
© 2013 thepharmaletter.com